Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial-Reference-Cited by-同舟云学术

Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial

Published:2022-01 Issue: Volume:183 Page:109152
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Becker Frauke,Dakin Helen A.,Reed Shelby D.,Li Yanhong,Leal José,Gustavson Stephanie M.,Wittbrodt Eric,Hernandez Adrian F.,Gray Alastair M.,Holman Rury R.

Funder

MRC

NIHR

NIHR Oxford Biomedical Research Centre

Amylin Pharmaceuticals

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference30 articles.

1. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045;Cho;Diabetes Res Clin Pract,2018

2. Excess mortality among persons with type 2 diabetes;Tancredi;N Engl J Med,2015

3. The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity;Alva;Health Econ,2014

4. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials;Zoungas;Lancet Diabetes Endocrinol,2017

5. Intensive glucose control and macrovascular outcomes in type 2 diabetes;Turnbull;Diabetologia,2009

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management;PharmacoEconomics;2024-06-26

3. Bioactive alkaloidal and phenolic phytochemicals as promising epidrugs for diabetes mellitus 2: A review of recent development;Fitoterapia;2024-06

4. A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China;Clinical Drug Investigation;2023-03-21